Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 293,815	$ 339,154
Accounts receivable	50,000	2,045
Prepaid expenses and other current assets	10,926	9,022
Research and development incentives receivable	26,512	19,162
Total current assets	381,253	369,383
Property and equipment, net	18,261	19,110
Operating lease right-of-use assets	18,721	13,658
Other assets	10,566	8,458
Total assets	428,801	410,609
Current liabilities:
Accounts payable	2,813	6,472
Accrued expenses and other current liabilities	25,212	26,452
Deferred revenue, current portion	24,970	20,418
Total current liabilities	52,995	53,342
Long-term debt, net of discount	30,417	30,315
Operating lease liabilities, net of current portion	14,394	10,885
Deferred revenue, net of current portion	83,751	41,455
Other long-term liabilities	4,081	3,829
Total liabilities	185,638	139,826
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, £0.01 nominal value; 59,612,613 and 57,820,181 shares authorized at March 31, 2023 and December 31, 2022, respectively; 30,031,758 and 29,873,893 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	389	387
Additional paid-in capital	612,863	601,105
Accumulated other comprehensive income	71	387
Accumulated deficit	(370,160)	(331,096)
Total shareholders' equity	243,163	270,783
Total liabilities and shareholders' equity	$ 428,801	$ 410,609